Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer

Cristina Gutierrez, Colleen McEvoy, Laveena Munshi, R. Scott Stephens, Michael E. Detsky, Joseph L. Nates, Stephen M. Pastores

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: To describe the most common serious adverse effects and organ toxicities associated with emerging therapies for cancer that may necessitate admission to the ICU. DATA SOURCES AND STUDY SELECTION: PubMed and Medline search of relevant articles in English on the management of adverse effects of immunotherapy for cancer. DATA EXTRACTION AND DATA SYNTHESIS: Targeted therapies including tyrosine kinase inhibitors, monoclonal antibodies, checkpoint inhibitors, and immune effector cell therapy have improved the outcome and quality of life of patients with cancer. However, severe and life-threatening side effects can occur. These toxicities include infusion or hypersensitivity reactions, cytokine release syndrome, pulmonary, cardiac, renal, hepatic, and neurologic toxicities, hemophagocytic lymphohistiocytosis, opportunistic infections, and endocrinopathies. Cytokine release syndrome is the most common serious toxicity after administration of monoclonal antibodies and immune effector cell therapies. Most of the adverse events from immunotherapy results from an exaggerated T-cell response directed against normal tissue, resulting in the generation of high levels of proinflammatory cytokines. Toxicities from targeted therapies are usually secondary to "on target toxicities." Management is largely supportive and may include discontinuation of the specific agent, corticosteroids, and other immune suppressing agents for severe (grade 3 or 4) immune-related adverse events like neurotoxicity and pneumonitis. CONCLUSIONS: The complexity of toxicities associated with modern targeted and immunotherapeutic agents for cancer require a multidisciplinary approach among ICU staff, oncologists, and organ specialists and adoption of standardized treatment protocols to ensure the best possible patient outcomes.

Original languageEnglish (US)
Pages (from-to)10-21
Number of pages12
JournalCritical care medicine
Volume48
Issue number1
DOIs
StatePublished - Jan 1 2020

Fingerprint

Critical Care
Immunotherapy
Cytokines
Cell- and Tissue-Based Therapy
Neoplasms
Monoclonal Antibodies
Hemophagocytic Lymphohistiocytosis
Information Storage and Retrieval
Opportunistic Infections
Clinical Protocols
PubMed
Protein-Tyrosine Kinases
Nervous System
Pneumonia
Adrenal Cortex Hormones
Hypersensitivity
Therapeutics
Quality of Life
T-Lymphocytes
Liver

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer. / Gutierrez, Cristina; McEvoy, Colleen; Munshi, Laveena; Stephens, R. Scott; Detsky, Michael E.; Nates, Joseph L.; Pastores, Stephen M.

In: Critical care medicine, Vol. 48, No. 1, 01.01.2020, p. 10-21.

Research output: Contribution to journalArticle

Gutierrez, Cristina ; McEvoy, Colleen ; Munshi, Laveena ; Stephens, R. Scott ; Detsky, Michael E. ; Nates, Joseph L. ; Pastores, Stephen M. / Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer. In: Critical care medicine. 2020 ; Vol. 48, No. 1. pp. 10-21.
@article{e42077c9418e49e0a07657200b55cb97,
title = "Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer",
abstract = "OBJECTIVES: To describe the most common serious adverse effects and organ toxicities associated with emerging therapies for cancer that may necessitate admission to the ICU. DATA SOURCES AND STUDY SELECTION: PubMed and Medline search of relevant articles in English on the management of adverse effects of immunotherapy for cancer. DATA EXTRACTION AND DATA SYNTHESIS: Targeted therapies including tyrosine kinase inhibitors, monoclonal antibodies, checkpoint inhibitors, and immune effector cell therapy have improved the outcome and quality of life of patients with cancer. However, severe and life-threatening side effects can occur. These toxicities include infusion or hypersensitivity reactions, cytokine release syndrome, pulmonary, cardiac, renal, hepatic, and neurologic toxicities, hemophagocytic lymphohistiocytosis, opportunistic infections, and endocrinopathies. Cytokine release syndrome is the most common serious toxicity after administration of monoclonal antibodies and immune effector cell therapies. Most of the adverse events from immunotherapy results from an exaggerated T-cell response directed against normal tissue, resulting in the generation of high levels of proinflammatory cytokines. Toxicities from targeted therapies are usually secondary to {"}on target toxicities.{"} Management is largely supportive and may include discontinuation of the specific agent, corticosteroids, and other immune suppressing agents for severe (grade 3 or 4) immune-related adverse events like neurotoxicity and pneumonitis. CONCLUSIONS: The complexity of toxicities associated with modern targeted and immunotherapeutic agents for cancer require a multidisciplinary approach among ICU staff, oncologists, and organ specialists and adoption of standardized treatment protocols to ensure the best possible patient outcomes.",
author = "Cristina Gutierrez and Colleen McEvoy and Laveena Munshi and Stephens, {R. Scott} and Detsky, {Michael E.} and Nates, {Joseph L.} and Pastores, {Stephen M.}",
year = "2020",
month = "1",
day = "1",
doi = "10.1097/CCM.0000000000004087",
language = "English (US)",
volume = "48",
pages = "10--21",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer

AU - Gutierrez, Cristina

AU - McEvoy, Colleen

AU - Munshi, Laveena

AU - Stephens, R. Scott

AU - Detsky, Michael E.

AU - Nates, Joseph L.

AU - Pastores, Stephen M.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - OBJECTIVES: To describe the most common serious adverse effects and organ toxicities associated with emerging therapies for cancer that may necessitate admission to the ICU. DATA SOURCES AND STUDY SELECTION: PubMed and Medline search of relevant articles in English on the management of adverse effects of immunotherapy for cancer. DATA EXTRACTION AND DATA SYNTHESIS: Targeted therapies including tyrosine kinase inhibitors, monoclonal antibodies, checkpoint inhibitors, and immune effector cell therapy have improved the outcome and quality of life of patients with cancer. However, severe and life-threatening side effects can occur. These toxicities include infusion or hypersensitivity reactions, cytokine release syndrome, pulmonary, cardiac, renal, hepatic, and neurologic toxicities, hemophagocytic lymphohistiocytosis, opportunistic infections, and endocrinopathies. Cytokine release syndrome is the most common serious toxicity after administration of monoclonal antibodies and immune effector cell therapies. Most of the adverse events from immunotherapy results from an exaggerated T-cell response directed against normal tissue, resulting in the generation of high levels of proinflammatory cytokines. Toxicities from targeted therapies are usually secondary to "on target toxicities." Management is largely supportive and may include discontinuation of the specific agent, corticosteroids, and other immune suppressing agents for severe (grade 3 or 4) immune-related adverse events like neurotoxicity and pneumonitis. CONCLUSIONS: The complexity of toxicities associated with modern targeted and immunotherapeutic agents for cancer require a multidisciplinary approach among ICU staff, oncologists, and organ specialists and adoption of standardized treatment protocols to ensure the best possible patient outcomes.

AB - OBJECTIVES: To describe the most common serious adverse effects and organ toxicities associated with emerging therapies for cancer that may necessitate admission to the ICU. DATA SOURCES AND STUDY SELECTION: PubMed and Medline search of relevant articles in English on the management of adverse effects of immunotherapy for cancer. DATA EXTRACTION AND DATA SYNTHESIS: Targeted therapies including tyrosine kinase inhibitors, monoclonal antibodies, checkpoint inhibitors, and immune effector cell therapy have improved the outcome and quality of life of patients with cancer. However, severe and life-threatening side effects can occur. These toxicities include infusion or hypersensitivity reactions, cytokine release syndrome, pulmonary, cardiac, renal, hepatic, and neurologic toxicities, hemophagocytic lymphohistiocytosis, opportunistic infections, and endocrinopathies. Cytokine release syndrome is the most common serious toxicity after administration of monoclonal antibodies and immune effector cell therapies. Most of the adverse events from immunotherapy results from an exaggerated T-cell response directed against normal tissue, resulting in the generation of high levels of proinflammatory cytokines. Toxicities from targeted therapies are usually secondary to "on target toxicities." Management is largely supportive and may include discontinuation of the specific agent, corticosteroids, and other immune suppressing agents for severe (grade 3 or 4) immune-related adverse events like neurotoxicity and pneumonitis. CONCLUSIONS: The complexity of toxicities associated with modern targeted and immunotherapeutic agents for cancer require a multidisciplinary approach among ICU staff, oncologists, and organ specialists and adoption of standardized treatment protocols to ensure the best possible patient outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85076449040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076449040&partnerID=8YFLogxK

U2 - 10.1097/CCM.0000000000004087

DO - 10.1097/CCM.0000000000004087

M3 - Article

C2 - 31725440

AN - SCOPUS:85076449040

VL - 48

SP - 10

EP - 21

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 1

ER -